Pharma/Biotech Update: New Hemophilia A Drug Gets Approval in Canada
November 11, 2014; Posted by: WeBleed staff
Octapharma’s Nuwiq gets approval in Canada.
According to a release today from the Pharmaceutical Business Review (PBR), a new hemophilia A (factor VIII deficiency) medication looks to be hitting the shelves in Canada soon. Octapharma received the okay from Health Canada for treatment and prophylaxis of bleeding in patients of all ages suffering with hemophilia A with their new drug called Nuwiq.
“The way Nuwiq is produced is exciting as it allows the molecule to closely resemble the naturally occurring FVIII,” says McMaster Children’s Hospital professor Pediatrics and director of the Hemophilia Program Dr. Anthony Chan. “Health Canada’s approval of Nuwiq® provides patients with hemophilia A a new recombinant product option that will allow further customisation of hemophilia treatment on an individual basis.”
Other countries reviewing Nuwiq for approval include Australia, the European Union and the United States.
Photo Credit – Octapharma
webleed.org – your source for bleeding news!